William T. Barry

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

Melinda L. Telli, Kirsten M. Timms, Julia Reid et al. · Clinical Cancer Research · 2016 · 1.2K citations · Full text

Medicine, Genetics, Oncology +17

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

Sara M. Tolaney, William T. Barry, Chau T. Dang et al. · New England Journal of Medicine · 2015 · 748 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

Shaokun Shu, Charles Y. Lin, Housheng Hansen He et al. · Nature · 2016 · 629 citations · Full text

Medicine, Oncology, Pharmacology +14

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

Joyce F. Liu, William T. Barry, Michael J. Birrer et al. · The Lancet Oncology · 2014 · 584 citations · Full text

Medicine, Gynecology, Oncology +16

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

Lisa A. Carey, Donald A. Berry, Constance Cirrincione et al. · Journal of Clinical Oncology · 2015 · 437 citations · Full text

Medicine, Oncology, Pharmacology +17